Sequential Therapies After Osteoanabolic Treatment
ConditionOsteoporosis, Postmenopausal
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age50-85
Sponsor424 General Military Hospital
About this trial
12-month prospective, open-label, multicenter, international, observational study evaluating sequential treatments after osteoanabolics
Eligibility criteria
Qualifiers
None
Disqualifiers
a bone disease other than postmenopausal osteoporosis
use of medications other than romosozumab or teriparatide affecting bone metabolism during the last 12 months before entering the study
creatinine clearance <60 mL/min/1.73 m2
liver failure
Trial design
Treatments tested in this trial
- Zoledronate
- Denosumab
- Teriparatide
- Romosozumab
- Abaloparatide Injection (80 mcg)
Treatment groups
150 Participants
are divided into 6 treatment groups6
Treatment groupsSee each treatment group below.
Sponsors and collaborators
424 General Military Hospital
Lead sponsor
Laikο General Hospital, Athens
Collaborator
251 Hellenic Air Force & VA General Hospital
Collaborator
KAT Hospital of Athens
Collaborator
Campus Biomedico - Roma
Collaborator
Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico Milano
Collaborator
Azienda Ospedaliero Universitaria, Santa Maria della Misericordia di Udine, Italy
Collaborator
University of Siena
Collaborator
Source ClinicalTrials.gov